Notably the study of Jones et al. showed that CD4 and CD8 cell reconstitution was similar between patients with and without secondary autoimmunity, suggesting that the rate of T cell reconstitution and T cell number itself may not be a useful measurement to predict outcome in Alemtuzumab treated MS patients (7). Here, CD8A is linked to Autoimmunity.